Su Hua

发表

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Makoto Nishio, Peter McNamara, Ryohei Katayama, 2014, Cancer discovery.

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Glen Spraggon, Scott A Lesley, Nanxin Li, 2010, The Biochemical journal.

Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.

Nanxin Li, J. Shaffer, S. Kasibhatla, 2020, ACS medicinal chemistry letters.